Revolution Ebitda from 2010 to 2025

RVMDW Stock   0.07  0.00  0.000004%   
Revolution Medicines, EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA is likely to outpace its year average in 2025. During the period from 2010 to 2025, Revolution Medicines, EBITDA regression line of quarterly data had mean square error of 19440.7 T and geometric mean of  154,289,047. View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-689.5 M
Current Value
-655 M
Quarterly Volatility
201.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Revolution Medicines, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Revolution Medicines,'s main balance sheet or income statement drivers, such as Net Interest Income of 91.2 M, Interest Income of 91.2 M or Interest Expense of 331 K, as well as many indicators such as Price To Sales Ratio of 265, Dividend Yield of 0.0 or PTB Ratio of 3.08. Revolution financial statements analysis is a perfect complement when working with Revolution Medicines, Valuation or Volatility modules.
  
Check out the analysis of Revolution Medicines, Correlation against competitors.

Latest Revolution Medicines,'s Ebitda Growth Pattern

Below is the plot of the Ebitda of Revolution Medicines, Warrant over the last few years. It is Revolution Medicines,'s EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Revolution Medicines,'s overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Revolution Ebitda Regression Statistics

Arithmetic Mean(207,213,988)
Geometric Mean154,289,047
Coefficient Of Variation(97.07)
Mean Deviation148,220,856
Median(101,914,000)
Standard Deviation201,135,961
Sample Variance40455.7T
Range587.6M
R-Value(0.74)
Mean Square Error19440.7T
R-Squared0.55
Significance0.001
Slope(31,373,693)
Total Sum of Squares606835.1T

Revolution Ebitda History

2025-655 M
2024-689.5 M
2023-430.6 M
2022-239.5 M
2021-179.7 M

About Revolution Medicines, Financial Statements

Revolution Medicines, investors use historical fundamental indicators, such as Revolution Medicines,'s Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Revolution Medicines,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-689.5 M-655 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Revolution Stock Analysis

When running Revolution Medicines,'s price analysis, check to measure Revolution Medicines,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines, is operating at the current time. Most of Revolution Medicines,'s value examination focuses on studying past and present price action to predict the probability of Revolution Medicines,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines,'s price. Additionally, you may evaluate how the addition of Revolution Medicines, to your portfolios can decrease your overall portfolio volatility.